1. What is the rationale for the use of sotagliflozin in as an adjunct to insulin therapy in type 1 diabetes (T1D)? (0:05)
2. What clinical evidence supports the use of sotagliflozin in T1D? (1:00)
3. What is the effect of sotagliflozin on the risk of diabetic ketoacidosis and urinary tract infections? (1:57)
4. Which patients are most likely to benefit from this treatment? (2:58)
5. What further research is needed before this treatment enters routine clinical use?
